Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...

Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.